Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Pivotal bioVenture Partners is a life sciences venture capital firm founded in 2017 and headquartered in San Francisco, California. The firm operates additional offices in Boston, Massachusetts, Shanghai, and Hong Kong. As the primary venture capital arm of Pivotal Life Sciences, which is part of the Nan Fung Group, Pivotal bioVenture Partners has a total commitment of $689 million across its funds. The Nan Fung Group, a Hong Kong conglomerate established in 1954, provides a stable financial foundation for the firm, which has over $3 billion in total assets under management across all Nan Fung Life Sciences vehicles.
Pivotal bioVenture Partners specializes in investing in high-impact therapeutic innovations that address significant unmet medical needs. The firm supports both established companies and new ventures within the healthcare sector, focusing on transformative therapeutic solutions. The firm’s investment strategy is designed to leverage its extensive network and resources to enhance the growth potential of its portfolio companies.
Pivotal bioVenture Partners specializes in venture building within the life sciences sector, targeting transformative therapeutic innovations. The firm invests in companies developing high-impact therapeutics, particularly those utilizing AI and data analytics to improve their processes. Their investment strategy spans various stages, from seed funding to growth equity, with check sizes ranging from $1 million to $50 million.
The firm primarily focuses on North America, Europe, and Greater China, seeking to address significant unmet medical needs through its investments. Pivotal bioVenture Partners looks for companies that demonstrate strong potential for innovation and impact in the healthcare space. Their dual-track structure allows them to capitalize on cross-border deal flow, enhancing their investment opportunities in both Western and Asian markets.
Pivotal bioVenture Partners has built a notable portfolio of companies within the life sciences sector. Key investments include:
This diverse portfolio reflects Pivotal bioVenture Partners' commitment to investing in transformative healthcare solutions that address critical medical challenges.
To pitch Pivotal bioVenture Partners, founders should use the contact page on their website. A well-structured pitch deck is essential, including details on the company's vision, market opportunity, and how the solution addresses unmet medical needs. The firm prefers to see a clear articulation of the business model and competitive landscape.
Response times can vary, but founders should expect a thorough review process. Warm introductions are beneficial, as they can facilitate initial conversations with the investment team.
In December 2023, Pivotal bioVenture Partners announced the closing of its second fund, raising $389 million to continue its focus on therapeutic innovations in healthcare. This follows the successful launch of its inaugural fund in 2017, which raised $300 million.
Additionally, the firm participated in significant funding rounds for its portfolio companies, including a $50 million Series B investment in Evommune and a $225 million Series C funding round for Maplight Therapeutics, both in 2023. These investments highlight Pivotal bioVenture Partners' active role in supporting the growth of transformative healthcare companies.
What investment criteria does Pivotal bioVenture Partners use?
Pivotal bioVenture Partners focuses on transformative therapeutic innovations within the life sciences sector. They seek companies that address significant unmet medical needs and demonstrate strong potential for impact and innovation.
How can founders pitch to Pivotal bioVenture Partners?
Founders can reach out through the firm's contact page. It is advisable to include a detailed pitch deck that outlines the company's vision, market opportunity, and how their solution addresses unmet medical needs.
What makes Pivotal bioVenture Partners different from other VCs?
The firm combines venture building with a strong financial backing from the Nan Fung Group, allowing for long-term investments in high-impact therapeutic innovations. Their dual-track investment strategy provides a unique advantage in accessing cross-border deal flow.
What is the geographic scope of Pivotal bioVenture Partners?
Pivotal bioVenture Partners primarily invests in North America, Europe, and Greater China, leveraging its global presence to identify and support promising healthcare innovations.
What is the typical check size for investments?
The firm typically invests between $1 million and $50 million in its portfolio companies, depending on the stage and potential of the business.
What kind of post-investment support does Pivotal bioVenture Partners provide?
Pivotal bioVenture Partners adds value through strategic support in venture building, access to a robust network, and leveraging the financial stability provided by the Nan Fung Group's diverse investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.